Synthesis and in vitro calcium antagonist activity of 4-aryl-7,7-dimethyl/1,7,7-trimethyl-1,2,3,4,5,6,7,8-octahydroquinazoline-2,5-dione derivatives

Kappe, 1993, 100 years of the Biginelli dihydropyrimidine synthesis, Tetrahedron, 49, 6937, 10.1016/S0040-4020(01)87971-0

Atwal, 1990, Dihydropyrimidine calcium channel blockers: 2-Heterosubstituted 4-aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic acid esters as potent mimics of dihydropyridines, J. Med. Chem., 33, 1510, 10.1021/jm00167a035

Atwal, 1990, Dihydropyrimidine calcium channel blockers. 2. 3-Substituted-4-aryl-1,4-dihydro-6-methyl-5-pyrimidine-carboxylic acid esters as potent mimics of dihydropyridines, J. Med. Chem., 33, 2629, 10.1021/jm00171a044

Atwal, 1991, Dihydropyrimidine calcium channel blockers. 3. 3-Carbamoyl-4-aryl-1,2,3,4-tetrahydro-6-methyl-5-pyrimidinecarboxylic acid esters as orally effective antihypertensive agents, J. Med. Chem., 34, 806, 10.1021/jm00106a048

Grover, 1995, Pharmacologic profile of the dihydropyrimidine calcium channel blockers SQ 32 547 and SQ 32 946, J. Cardiovasc. Pharmacol., 26, 289, 10.1097/00005344-199508000-00015

Kappe, 2000, Biologically active dihydropyrimidones of the Biginelli-type—a literature survey, Eur. J. Med. Chem., 35, 1043, 10.1016/S0223-5234(00)01189-2

Saraç, 1997, 4-Aryl-5-oxo-1,2,3,4,5,6,7,8-octahydroquinazoline-2-thione derivatives: synthesis, enantiomeric separation and in vitro screening as calcium antagonists, Boll. Chim. Farm., 136, 657

Saraç, 1998, Synthesis, chemical and pharmacological properties of some 4-aryl-1,2,3,4,5,6,7,8-octahydroquinazoline-2,5-diones, Pharmazie, 53, 91

Saraç, 2001, 4-Aryl-6,6-dimethyl-1,2,3,4,5,6,7,8-octahydroquinazoline-2,5-diones: synthesis, chromatographic resolution and pharmacological activity, Pharmazie, 56, 298

Yarım, 2002, Synthesis, enantioseparation and pharmacological activity of 4-aryl-7,7-dimethyl-5-oxo-1,2,3,4,5,6,7,8-octahydroquinazoline-2-thiones, Arzneim.-Forsch. Drug Res., 52, 27

Biginelli, 1891, Ueber Aldeyhduramide des Acetessigäthers, Chem. Ber., 24, 1317, 10.1002/cber.189102401228

Candan, 2001, Crystal structure of 1,7,7-trimethyl-4-(4-methylphenyl)-1,2,3,4,5,6,7,8-octahydroquinazoline-2,5-dione, Anal. Sci., 17, 681, 10.2116/analsci.17.681

Candan, 2001, Crystal structure of 4-(4-bromophenyl)-1,7,7-trimethyl-1,2,3,4,5,6,7,8-octahydroquinazoline-2,5-dione, Anal. Sci., 17, 1023, 10.2116/analsci.17.1023

O'Reilly, 1987, Synthesis of substituted 1,2,3,4-tetrahydro-6-methyl-2-oxo-5-pyrimidinecarboxylic acid esters: the Biginelli condensation revisited, Heterocycles, 26, 1185, 10.3987/R-1987-05-1185

Sadanandam, 1992, Synthesis and biological evaluation of new 3,4-dihydro-6-methyl-5-N-methylcarbamoyl-4-(substituted phenyl)-2(1H)-pyrimidinones and pyrimidinethiones, Eur. J. Med. Chem., 27, 87, 10.1016/0223-5234(92)90066-A

Pretsch, 1983

Mayer, 1998, Electron impact induced fragmentation of 4-aryl-4,6,7,8-tetrahydro-1H,3H-quinazoline-2,5-diones, Heterocycles, 48, 1169, 10.3987/COM-98-8133

Drayer, 1986, Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: an overview, Clin. Pharmacol. Ther., 40, 125, 10.1038/clpt.1986.150

Rovnyak, 1995, Calcium entry blockers and activators: conformational and structural determinants of dihydropyrimidine calcium channel modulators, J. Med. Chem., 38, 119, 10.1021/jm00001a017

M. Yarım, S. Saraç, Enantiomeric separation of 4-aryl-7,7-dimethyl/1,7,7-trimethyl-1,2,3,4,5,6,7,8-octahydroquinazoline-2,5-diones by chiral HPLC, Chromatographia 56 (2002) 307.

Rose, 1989, Kalzium-modulatoren von typ annelierter Dihydropyridine, Synthese und pharmakologische Wirkung, Arzneim.-Forsch. Drug Res., 39, 1393

Rose, 1990, 5-Oxo-1,4-dihydroindenopyridines. Calcium modulators with partial calcium agonistic activity, J. Heterocycl. Chem., 27, 237, 10.1002/jhet.5570270223

Rose, 1991, Synthesis and pharmacological activities of calcium modulatory hexahydroquinolinones, J. Heterocycl. Chem., 28, 2005, 10.1002/jhet.5570280836

Kazda, 1980, Pharmacology of a new calcium antagonistic compound, isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridine-dicarboxylate (Nisoldipine, Bay K 5552), Arzneim.-Forsch. Drug Res., 30, 2144

Şafak, 1993, Synthesis of some 1,4,5,6,7,8-hexahydroquinoline derivatives and their calcium antagonistic activity, Arzneim.-Forsch./Drug Res., 43, 1052

Rose, 1992, Synthesis, configuration and calcium modulatory properties of enantiomerically pure 5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylates, J. Med. Chem., 35, 2238, 10.1021/jm00090a014

Şafak, 1995, 3-Acetyl-4-aryl-5-oxo-2,7,7-trimethyl-1,4,5,6,7,8-hexahydroquinoline derivatives and their calcium antagonistic activities, Arzneim.-Forsch./Drug Res., 45, 1154

Spedding, 1984, Calcium antagonists: a class of drugs with a bright future. Part II. Determination of basic pharmacological properties, Life Sci., 35, 575, 10.1016/0024-3205(84)90252-2